Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""VACCINES"" wg kryterium: Temat


Tytuł :
Effect of cytomegalovirus infection on humoral immune responses to select vaccines administered during infancy.
Autorzy :
Pathirana J; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Electronic address: .
Kwatra G; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Clinical Microbiology, Christian Medical College, Vellore, India.
Maposa I; Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
Groome MJ; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Madhi SA; Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Pokaż więcej
Źródło :
Vaccine [Vaccine] 2021 Aug 09; Vol. 39 (34), pp. 4793-4799. Date of Electronic Publication: 2021 Jul 16.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cytomegalovirus Infections*/prevention & control
Diphtheria*
Diphtheria-Tetanus-acellular Pertussis Vaccines*
Haemophilus Vaccines*
Tetanus*
Antibodies, Bacterial ; Child ; Diphtheria-Tetanus-Pertussis Vaccine ; Hepatitis B Vaccines ; Humans ; Immunity, Humoral ; Infant ; Infant, Newborn ; Poliovirus Vaccine, Inactivated ; Vaccines, Combined ; Vaccines, Conjugate
Czasopismo naukowe
Tytuł :
A global agenda for older adult immunization in the COVID-19 era: A roadmap for action.
Autorzy :
Privor-Dumm LA; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Poland GA; Mayo Vaccine Research Group, Mayo Clinic and Foundation, Rochester, MN, USA.
Barratt J; International Federation on Ageing, Toronto, Canada.
Durrheim DN; Public Health Medicine, University of Newcastle, Wallsend, NSW, Australia.
Deloria Knoll M; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Vasudevan P; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Jit M; Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, England, United Kingdom.
Bonvehí PE; EMIC, Buenos Aires, Argentina.
Bonanni P; Department of Health Sciences, University of Florence, Florence, Italy.
Pokaż więcej
Corporate Authors :
International Council on Adult Immunization
Źródło :
Vaccine [Vaccine] 2021 Aug 31; Vol. 39 (37), pp. 5240-5250. Date of Electronic Publication: 2020 Jul 03.
Typ publikacji :
Clinical Conference
MeSH Terms :
COVID-19*
Influenza Vaccines*
Vaccines*
Aged ; COVID-19 Vaccines ; Humans ; Immunization ; Immunization Programs ; Pandemics ; SARS-CoV-2 ; Vaccination
Konferencja
Tytuł :
Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: preliminary results.
Autorzy :
Zee JST; Department of Pathology, Hong Kong Sanatorium and Hospital, Hong Kong.; Infection Control Team, Hong Kong Sanatorium and Hospital, Hong Kong.
Lai KTW; Department of Pathology, Hong Kong Sanatorium and Hospital, Hong Kong.
Ho MKS; Department of Pathology, Hong Kong Sanatorium and Hospital, Hong Kong.
Leung ACP; Department of Pathology, Hong Kong Sanatorium and Hospital, Hong Kong.
Chan QWL; Infection Control Team, Hong Kong Sanatorium and Hospital, Hong Kong.
Ma ESK; Department of Pathology, Hong Kong Sanatorium and Hospital, Hong Kong.
Lee KH; Hospital Administration, Hong Kong Sanatorium and Hospital, Hong Kong.
Lau CC; Hospital Administration, Hong Kong Sanatorium and Hospital, Hong Kong.
Yung RWH; Department of Pathology, Hong Kong Sanatorium and Hospital, Hong Kong.; Infection Control Team, Hong Kong Sanatorium and Hospital, Hong Kong.; Hospital Administration, Hong Kong Sanatorium and Hospital, Hong Kong.
Pokaż więcej
Źródło :
Hong Kong medical journal = Xianggang yi xue za zhi [Hong Kong Med J] 2021 Aug; Vol. 27 (4), pp. 312-313. Date of Electronic Publication: 2021 Jun 24.
Typ publikacji :
Comparative Study; Letter
MeSH Terms :
COVID-19 Vaccines*/administration & dosage
COVID-19 Vaccines*/immunology
Immunogenicity, Vaccine*
COVID-19/*prevention & control
Health Personnel/*statistics & numerical data
Adult ; Antibodies, Neutralizing/blood ; COVID-19/epidemiology ; Female ; Hong Kong/epidemiology ; Humans ; Immunoglobulin G/blood ; Male ; Middle Aged ; SARS-CoV-2 ; Serologic Tests/methods ; Serologic Tests/statistics & numerical data ; Spike Glycoprotein, Coronavirus/immunology ; Vaccines, Inactivated/administration & dosage ; Vaccines, Inactivated/immunology ; Vaccines, Synthetic/administration & dosage ; Vaccines, Synthetic/immunology
Raport
Tytuł :
Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2.
Autorzy :
Granados-Riveron JT; Laboratorio de Investigación en Patogénesis Molecular, Hospital Infantil de México, Federico Gómez, Ciudad de México, Mexico.
Aquino-Jarquin G; Laboratorio de Investigación en Genómica, Genética y Bioinformática, Hospital Infantil de México, Federico Gómez, Ciudad de México, Mexico. Electronic address: .
Pokaż więcej
Źródło :
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2021 Oct; Vol. 142, pp. 111953. Date of Electronic Publication: 2021 Jul 23.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Biomedical Engineering*/methods
Biomedical Engineering*/trends
COVID-19*/prevention & control
COVID-19*/virology
COVID-19 Vaccines*/classification
COVID-19 Vaccines*/pharmacology
SARS-CoV-2*/drug effects
SARS-CoV-2*/immunology
Drug Development/*methods
Drug Discovery/*methods
Drug Delivery Systems/methods ; Humans ; Immunogenicity, Vaccine ; Liposomes/pharmacology ; Nanoparticles ; Nucleosides/pharmacology ; Nucleosides/physiology ; Spike Glycoprotein, Coronavirus/immunology ; Vaccines, Synthetic/pharmacology
Czasopismo naukowe
Tytuł :
Effectiveness of an Inactivated SARS-CoV-2 Vaccine. Reply.
Autorzy :
Jara A; Pontificia Universidad Católica de Chile, Santiago, Chile.
Undurraga EA; Pontificia Universidad Católica de Chile, Santiago, Chile.
Araos R; Universidad del Desarrollo, Santiago, Chile .
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Sep 30; Vol. 385 (14), pp. 1338-1339. Date of Electronic Publication: 2021 Sep 15.
Typ publikacji :
Letter; Comment
MeSH Terms :
COVID-19*
Viral Vaccines*
COVID-19 Vaccines ; Humans ; SARS-CoV-2 ; Vaccines, Inactivated
Opinia redakcyjna
Tytuł :
Effectiveness of an Inactivated SARS-CoV-2 Vaccine.
Autorzy :
Chi H; MacKay Children's Hospital, Taipei, Taiwan.
Chiu NC; MacKay Children's Hospital, Taipei, Taiwan.
Lin CY; Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan .
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Sep 30; Vol. 385 (14), pp. 1337-1338. Date of Electronic Publication: 2021 Sep 15.
Typ publikacji :
Letter; Comment
MeSH Terms :
COVID-19*
Viral Vaccines*
COVID-19 Vaccines ; Humans ; SARS-CoV-2 ; Vaccines, Inactivated
Opinia redakcyjna
Tytuł :
Effectiveness of an Inactivated SARS-CoV-2 Vaccine.
Autorzy :
Onishi FJ; Universidade Federal de São Paulo, São Paulo, Brazil .
Goto JM; Hospital do Coração, São Paulo, Brazil.
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Sep 30; Vol. 385 (14), pp. 1338. Date of Electronic Publication: 2021 Sep 15.
Typ publikacji :
Letter; Comment
MeSH Terms :
COVID-19*
Viral Vaccines*
COVID-19 Vaccines ; Humans ; SARS-CoV-2 ; Vaccines, Inactivated
Opinia redakcyjna
Tytuł :
Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children.
Autorzy :
Patel PD; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Patel P; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Liang Y; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Meiring JE; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Misiri T; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Mwakiseghile F; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Tracy JK; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Masesa C; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Msuku H; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Banda D; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Mbewe M; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Henrion M; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Adetunji F; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Simiyu K; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Rotrosen E; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Birkhold M; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Nampota N; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Nyirenda OM; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Kotloff K; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Gmeiner M; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Dube Q; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Kawalazira G; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Laurens MB; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Heyderman RS; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Gordon MA; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Neuzil KM; From the Malawi-Liverpool-Wellcome Program (P.D.P., P.P., J.E.M., T.M., F.M., C.M., H.M., D.B., M.M., M.H., M.G., M.A.G.), the Blantyre Malaria Project (N.N., O.M.N.), the Department of Paediatrics, Queen Elizabeth Central Hospital (Q.D.), the District Health Office, Blantyre District Council (G.K.), and Kamuzu University of Health Sciences (M.A.G.) - all in Blantyre, Malawi; the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (Y.L., J.K.T., F.A., K.S., E.R., M.B., K.K., M.B.L., K.M.N.); and Oxford Vaccine Group, the Department of Paediatrics, Oxford University, Oxford (J.E.M.), Liverpool School of Tropical Medicine (C.M., M.H., M.G.), and the Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool (M.A.G.), and the Division of Infection and Immunity, University College London, London (R.S.H.) - all in the United Kingdom.
Pokaż więcej
Corporate Authors :
TyVAC Malawi Team
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Sep 16; Vol. 385 (12), pp. 1104-1115.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Polysaccharides, Bacterial*/adverse effects
Typhoid-Paratyphoid Vaccines*/adverse effects
Typhoid Fever/*prevention & control
Child ; Child, Preschool ; Double-Blind Method ; Female ; Follow-Up Studies ; Humans ; Incidence ; Infant ; Intention to Treat Analysis ; Malawi ; Male ; Meningococcal Vaccines/adverse effects ; Salmonella typhi ; Typhoid Fever/epidemiology ; Vaccines, Conjugate
Czasopismo naukowe
Tytuł :
Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
Autorzy :
Forrat R; Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France.
Dayan GH; Clinical Sciences Sanofi Pasteur, Swiftwater, Pennsylvania, USA.
DiazGranados CA; Clinical Sciences Sanofi Pasteur, Swiftwater, Pennsylvania, USA.
Bonaparte M; Translation Sciences and Biomarkers, Sanofi Pasteur, Swiftwater, Pennsylvania, USA.
Laot T; Global Clinical Science, Sanofi Pasteur, Taguig City, Philippines.
Capeding MR; Research Institute for Tropical Medicine, Medical Department, Muntinlupa, Philippines.
Sanchez L; Global Clinical Science, Sanofi Pasteur, Taguig City, Philippines.
Coronel DL; Clinical Sciences, Sanofi Pasteur, Mexico City, Mexico.
Reynales H; Centro de Atencion e Investigación Médica, Caimed S.A.S, Bogotá, Colombia.
Chansinghakul D; Research & Development, Sanofi Pasteur, Bangkok, Thailand.
Hadinegoro SRS; Cipto Mangunkusumo Hospital, University of Indonesia, Jakarta, Indonesia.
Perroud AP; Clinical Sciences, Sanofi Pasteur, São Paulo, Brazil.
Frago C; Clinical Sciences, Sanofi Pasteur, Singapore.
Zambrano B; Clinical Sciences, Sanofi Pasteur, Uruguay.
Machabert T; Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France.
Wu Y; Clinical Sciences Sanofi Pasteur, Swiftwater, Pennsylvania, USA.
Luedtke A; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Price B; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Vigne C; Clinical Sciences, Sanofi Pasteur, Marcy l'Etoile, France.
Haney O; Global Pharmacovigilance, Sanofi Pasteur, Swiftwater, Pennsylvania, USA.
Savarino SJ; Translation Sciences and Biomarkers, Sanofi Pasteur, Swiftwater, Pennsylvania, USA.
Bouckenooghe A; Clinical Sciences, Sanofi Pasteur, São Paulo, Brazil.
Noriega F; Clinical Sciences Sanofi Pasteur, Swiftwater, Pennsylvania, USA.
Pokaż więcej
Źródło :
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2021 Sep 15; Vol. 73 (6), pp. 1003-1012.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Dengue*/epidemiology
Dengue*/prevention & control
Dengue Vaccines*
Dengue Virus*
Severe Dengue*
Antibodies, Viral ; Asia/epidemiology ; Child ; Follow-Up Studies ; Humans ; Latin America/epidemiology ; Vaccines, Attenuated ; Vaccines, Combined
Czasopismo naukowe
Tytuł :
Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines.
Autorzy :
Gaspar EB; Animal Health Department, Embrapa Southern Region Animal Husbandry, Bagé, Brazil.
Prudencio CR; Department of Immunology, Adolfo Lutz Institute, São Paulo, Brazil.
De Gaspari E; Department of Immunology, Adolfo Lutz Institute, São Paulo, Brazil.
Pokaż więcej
Źródło :
Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2021 Sep 02; Vol. 17 (9), pp. 2965-2968. Date of Electronic Publication: 2021 May 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
COVID-19*
Meningococcal Vaccines*
Vaccines*
Bacterial Outer Membrane Proteins ; COVID-19 Vaccines ; Humans ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus
Czasopismo naukowe
Tytuł :
Countries with similar COVID-19 vaccination rates yet divergent outcomes: are all vaccines created equal?
Autorzy :
Alhinai ZA; Child Health Department, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman. Electronic address: .
Elsidig N; Child Health Department, Sultan Qaboos University Hospital, Muscat, Oman. Electronic address: .
Pokaż więcej
Źródło :
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2021 Sep; Vol. 110, pp. 258-260. Date of Electronic Publication: 2021 Jun 23.
Typ publikacji :
Journal Article
MeSH Terms :
COVID-19*
COVID-19 Vaccines*
Humans ; Pandemics ; SARS-CoV-2 ; Vaccination ; Vaccines, Inactivated
Czasopismo naukowe
Tytuł :
Development and characterization of a plant-derived rotavirus-like particle vaccine.
Autorzy :
Kurokawa N; Mitsubishi Tanabe Pharma Corporation, 17-10, Nihonbashi-Koamicho, Chuo-ku, Tokyo 103-8405, Japan. Electronic address: .
Lavoie PO; Medicago Inc., 1020 route de l'Église office 600, Québec, QC, Canada.
D'Aoust MA; Medicago Inc., 1020 route de l'Église office 600, Québec, QC, Canada.
Couture MM; Medicago Inc., 1020 route de l'Église office 600, Québec, QC, Canada.
Dargis M; Medicago Inc., 1020 route de l'Église office 600, Québec, QC, Canada.
Trépanier S; Medicago Inc., 1020 route de l'Église office 600, Québec, QC, Canada.
Hoshino S; Mitsubishi Tanabe Pharma Corporation, 1000, Kamoshida-cho, Aoba-ku, Yokohama, Kanagawa 227-0033, Japan.
Koike T; Mitsubishi Tanabe Pharma Corporation, Shonan Health Innovation Park, 2-26-1, Muraoka-Higashi, Fujisawa, Kanagawa 251-8555, Japan.
Arai M; Mitsubishi Tanabe Pharma Corporation, 1000, Kamoshida-cho, Aoba-ku, Yokohama, Kanagawa 227-0033, Japan.
Tsutsui N; Mitsubishi Tanabe Pharma Corporation, 17-10, Nihonbashi-Koamicho, Chuo-ku, Tokyo 103-8405, Japan.
Pokaż więcej
Źródło :
Vaccine [Vaccine] 2021 Aug 16; Vol. 39 (35), pp. 4979-4987. Date of Electronic Publication: 2021 Jul 26.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Rotavirus*/genetics
Rotavirus Infections*/prevention & control
Rotavirus Vaccines*
Vaccines, Virus-Like Particle*/genetics
Animals ; Antibodies, Viral ; Rabbits ; Rats ; Vaccines, Attenuated
Czasopismo naukowe
Tytuł :
Protective efficacy of a polyvalent influenza A DNA vaccine against both homologous (H1N1pdm09) and heterologous (H5N1) challenge in the ferret model.
Autorzy :
Guilfoyle K; National Institute for Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, EN6 3QG Hertfordshire, UK; Viroclinics Xplore, Nistelrooise Baan 3, 5374 Schaijk, The Netherlands(1).
Major D; National Institute for Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, EN6 3QG Hertfordshire, UK.
Skeldon S; National Institute for Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, EN6 3QG Hertfordshire, UK.
James H; National Institute for Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, EN6 3QG Hertfordshire, UK.
Tingstedt JL; Virus Research and Development Laboratory, Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark.
Polacek C; Virus Research and Development Laboratory, Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark.
Lassauniére R; Virus Research and Development Laboratory, Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark.
Engelhardt OG; National Institute for Biological Standards and Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, EN6 3QG Hertfordshire, UK. Electronic address: .
Fomsgaard A; Virus Research and Development Laboratory, Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark; Infectious Disease Research Unit, Clinical Institute, University of Southern Denmark, Sdr. Boulevard 29, DK-5000 Odense C, Denmark.
Pokaż więcej
Źródło :
Vaccine [Vaccine] 2021 Aug 09; Vol. 39 (34), pp. 4903-4913. Date of Electronic Publication: 2020 Oct 06.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Influenza A Virus, H1N1 Subtype*
Influenza A Virus, H5N1 Subtype*
Influenza Vaccines*
Influenza, Human*
Orthomyxoviridae Infections*/prevention & control
Vaccines, DNA*
Animals ; Antibodies, Viral ; Ferrets ; Humans ; Influenza A Virus, H3N2 Subtype ; Vaccines, Combined
Czasopismo naukowe
Tytuł :
One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model.
Autorzy :
Gooch KE; Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Smith TRF; Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA.
Salguero FJ; Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Fotheringham SA; Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Watson RJ; Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Dennis MJ; Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Handley A; Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Humphries HE; Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Longet S; Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Tipton T; Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Sarfas C; Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Sibley L; Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Slack GS; Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Rayner E; Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Ryan KA; Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Schultheis K; Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA.
Ramos SJ; Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA.
White A; Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Charlton S; Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Sharpe SA; Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Gleeson F; Department of Oncology, Oxford University, Oxford, UK.
Humeau LM; Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA.
Hall Y; Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Broderick KE; Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA.
Carroll MW; Public Health England (PHE), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom; Wellcome Centre for Human Genetics, Nuffield Dept of Medicine, Oxford University, OX3 7BN, UK.
Pokaż więcej
Źródło :
Vaccine [Vaccine] 2021 Aug 09; Vol. 39 (34), pp. 4885-4894. Date of Electronic Publication: 2021 Jun 23.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
COVID-19*
Vaccines, DNA*
Viral Vaccines*
Animals ; Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19 Vaccines ; Humans ; Macaca mulatta ; Pandemics ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus
Czasopismo naukowe
Tytuł :
Disproportionality analysis of reported drug adverse events to assess a potential safety signal for pentavalent vaccine in 2019 in El Salvador.
Autorzy :
Elas M; National Center for Pharmacovigilance, Ministry of Health, San Salvador, El Salvador; Master's and Graduate School, Faculty of Medicine, University of El Salvador, San Salvador, El Salvador. Electronic address: .
Villatoro N; National Vaccination and Inmunization Program, Ministry of Health, San Salvador, El Salvador. Electronic address: .
Pezzoli L; Independent Consultant, Geneva, Switzerland. Electronic address: .
Pokaż więcej
Źródło :
Vaccine [Vaccine] 2021 Aug 09; Vol. 39 (34), pp. 4849-4855. Date of Electronic Publication: 2021 Jul 16.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Haemophilus Vaccines*/adverse effects
Pharmaceutical Preparations*
Diphtheria-Tetanus-Pertussis Vaccine/adverse effects ; El Salvador ; Hepatitis B Vaccines/adverse effects ; Humans ; Infant ; Poliovirus Vaccine, Inactivated ; Vaccines, Combined/adverse effects
Czasopismo naukowe
Tytuł :
Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018-2019 Influenza Season in the United States.
Autorzy :
Boikos C; Seqirus Inc., Kirkland, Quebec, Canada.
Fischer L; Veradigm, San Francisco, California, USA.
O'Brien D; Veradigm, San Francisco, California, USA.
Vasey J; Veradigm, San Francisco, California, USA.
Sylvester GC; Seqirus USA Inc., Summit, New Jersey, USA.
Mansi JA; Seqirus Inc., Kirkland, Quebec, Canada.
Pokaż więcej
Źródło :
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2021 Aug 02; Vol. 73 (3), pp. e692-e698.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Influenza Vaccines*
Influenza, Human*/prevention & control
Adolescent ; Child ; Child, Preschool ; Humans ; Retrospective Studies ; Seasons ; United States/epidemiology ; Vaccines, Combined ; Vaccines, Inactivated
Czasopismo naukowe
Tytuł :
Covid 19 vaccination: Latest guidelines on blood donor deferral in India.
Autorzy :
Bhasker B; Department of Transfusion Medicine, Sparsh Hospital, Yeshwantpur, Bangalore. Electronic address: .
Pokaż więcej
Źródło :
Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine [Transfus Clin Biol] 2021 Aug; Vol. 28 (3), pp. 299. Date of Electronic Publication: 2021 May 28.
Typ publikacji :
Journal Article
MeSH Terms :
Blood Donors*
COVID-19 Vaccines*/administration & dosage
Practice Guidelines as Topic*
SARS-CoV-2*
Blood Banks/*standards
Blood Safety/*standards
COVID-19/*prevention & control
Donor Selection/*standards
Adolescent ; Adult ; COVID-19/epidemiology ; COVID-19/transmission ; Female ; Humans ; Immunization Programs ; Immunization Schedule ; Immunization, Secondary ; India ; Male ; Middle Aged ; Time Factors ; Vaccination ; Vaccination Coverage ; Vaccines, Attenuated ; Vaccines, Inactivated ; Young Adult
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies